Your browser doesn't support javascript.
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Lee, Holly; Tay, Jason; Duggan, Peter; McCulloch, Sylvia; Neri, Paola; Bahlis, Nizar J; Jimenez-Zepeda, Victor H.
  • Lee H; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Tay J; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Duggan P; Charbonneau Cancer Research Institute, Calgary, AB, Canada.
  • McCulloch S; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Neri P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Bahlis NJ; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
  • Jimenez-Zepeda VH; Charbonneau Cancer Research Institute, Calgary, AB, Canada.
Eur J Haematol ; 106(3): 340-345, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-944706
ABSTRACT

INTRODUCTION:

Patients with AL amyloidosis and immunoglobulin deposition diseases (IDD) are vulnerable during the COVID-19 pandemic due to the immune compromise from the plasma cell disorder and therapy-related immune defects. We describe a local experience in providing care for patients with AL amyloidosis and IDD.

METHOD:

Patient treatment and disease status since the beginning of the pandemic on March 11, 2020, as declared by WHO, were collected and analyzed.

RESULTS:

Ninety-six patients with AL amyloidosis and IDD were included. Four patients with IDD and 22 patients with systemic AL amyloidosis were receiving treatment during the pandemic. Since the pandemic, patients' treatments were discontinued if they achieved VGPR or better postinduction. Seven patients discontinued all treatment after achieving VGPR, and others required treatment modifications. 28 patients have been tested for COVID-19, and all tests have been negative. Three patients died since the pandemic, two from organ complications of systemic AL amyloidosis and one from an unrelated cause.

CONCLUSION:

The management of AL amyloidosis and IDD must be individualized on the clinical characteristics, centers' access to care under the pandemic restrictions, and the epidemiological aspects of the outbreak.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Paraproteinemias / Immunoglobulin Light Chains / Pandemics / Immunoglobulin Light-chain Amyloidosis / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Eur J Haematol Journal subject: Hematology Year: 2021 Document Type: Article Affiliation country: Ejh.13552

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Paraproteinemias / Immunoglobulin Light Chains / Pandemics / Immunoglobulin Light-chain Amyloidosis / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Eur J Haematol Journal subject: Hematology Year: 2021 Document Type: Article Affiliation country: Ejh.13552